Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Revenue (2016 - 2025)

Integra Lifesciences Holdings' Revenue history spans 17 years, with the latest figure at $434.9 million for Q4 2025.

  • For Q4 2025, Revenue fell 1.74% year-over-year to $434.9 million; the TTM value through Dec 2025 reached $1.6 billion, up 1.53%, while the annual FY2025 figure was $1.6 billion, 1.53% up from the prior year.
  • Revenue for Q4 2025 was $434.9 million at Integra Lifesciences Holdings, up from $402.1 million in the prior quarter.
  • Across five years, Revenue topped out at $442.6 million in Q4 2024 and bottomed at $360.1 million in Q1 2021.
  • The 5-year median for Revenue is $388.4 million (2021), against an average of $394.4 million.
  • The largest annual shift saw Revenue surged 50.77% in 2021 before it dropped 4.16% in 2023.
  • A 5-year view of Revenue shows it stood at $405.5 million in 2021, then fell by 1.85% to $398.0 million in 2022, then fell by 0.25% to $397.0 million in 2023, then grew by 11.49% to $442.6 million in 2024, then decreased by 1.74% to $434.9 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Revenue are $434.9 million (Q4 2025), $402.1 million (Q3 2025), and $415.6 million (Q2 2025).